Quantitative competitive reverse transcription-PCR as a method to evaluate retrovirus removal during chromatography...

Area of Science:

• Biotechnology
• Virology
• Pharmaceutical Manufacturing

Background:

• Chinese hamster ovary cells are used for pharmaceutical protein production and express retrovirus-like particles.
• Validating the clearance of these retroviral particles is essential for pharmaceutical product safety and registration.
• Xenotropic murine leukemia virus (X-MuLV) is a common model virus for these validation studies.

Purpose of the Study:

• To develop a method that can quantify both infectious and non-infectious X-MuLV.
• To differentiate viral inactivation from physical removal during chromatography processes.
• To provide a robust tool for validating retroviral clearance in pharmaceutical manufacturing.

Main Methods:

• Development of a quantitative competitive reverse transcription PCR (qRT-PCR) assay.
• Quantification of X-MuLV particle RNA (pRNA) in chromatography pools.
• Comparison of X-MuLV pRNA levels in load and elution pools to determine removal extent.

Main Results:

• The developed qRT-PCR method accurately quantifies X-MuLV particles, regardless of infectivity.
• The method successfully distinguishes between viral inactivation by low pH buffers and physical removal by chromatography.
• It provides a quantitative measure of X-MuLV removal by purification processes.

Conclusions:

• The quantitative PCR method is a powerful tool for assessing retroviral clearance in pharmaceutical manufacturing.
• It complements traditional cell-based infectivity assays by enabling the evaluation of physical removal.
• This method enhances the validation of manufacturing processes for ensuring pharmaceutical product safety.